Skip to main content
Erschienen in: Medical Oncology 4/2010

01.12.2010 | Original Paper

Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells

verfasst von: Aimin Zhang, Yi Liu, Yizheng Shen, Youhe Xu, Xiangtie Li

Erschienen in: Medical Oncology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Antiapoptosis and invasion are the causes for the failure of conventional radiotherapy and chemotherapy in human renal carcinomas. Osteopontin (OPN), a ligand for vß3 integrin and CD44 receptors, is a phosphorylated glycoprotein with diverse functions including tumorigenesis and tumor cell metastasis. Recently, OPN has been detected in human renal carcinomas and assessed as a potential prognostic marker of renal carcinomas. However, the function and mechanism of OPN in renal carcinomas remain unknown. In this study, we used OPN siRNA to silence the expression of OPN in renal carcinoma Caki-1 cells. Silent effect showed that sequence-specific siRNA targeting OPN suppressed OPN mRNA expression by 81% and OPN protein level by 91% in vitro. The apoptosis ability was significantly increased while the invasion ability was decreased in Caki-1 cells transfected with OPN siRNA. Western blot demonstrated that the effects of OPN silence were significantly accompanied by the activation of mitochondria-related apoptosis pathway involving cytochrome c, Apaf-1, cleaved caspase-3 and Bcl-2/Bax, and the downregulation of invasion-related proteins of MMP-2 and uPA expression. These results suggest that the downregulation of OPN expression can induce apoptosis increase and invasion suppression in renal carcinoma Caki-1 cells through mitochondria-related apoptosis pathway and MMP-2 and uPA-related invasion proteins, respectively.
Literatur
1.
Zurück zum Zitat Ng CS, et al. Diagnosis, staging, and surveillance. Am J Roentgenol. 2008;191:1220–32.CrossRef Ng CS, et al. Diagnosis, staging, and surveillance. Am J Roentgenol. 2008;191:1220–32.CrossRef
2.
Zurück zum Zitat Zisman A, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559–66.PubMedCrossRef Zisman A, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559–66.PubMedCrossRef
3.
Zurück zum Zitat Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl. 1998;30:92–102.PubMedCrossRef Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl. 1998;30:92–102.PubMedCrossRef
4.
Zurück zum Zitat Rittling SR, Denhardt DT. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol. 1999;7:103–13.PubMedCrossRef Rittling SR, Denhardt DT. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol. 1999;7:103–13.PubMedCrossRef
5.
Zurück zum Zitat Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001;1552:61–85.PubMed Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001;1552:61–85.PubMed
6.
Zurück zum Zitat Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008;68:152–61.PubMedCrossRef Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008;68:152–61.PubMedCrossRef
7.
Zurück zum Zitat Cheng J, et al. Human macrophages promote the motility and invasiveness of Osteopontin-knockdown tumor cells. Cancer Res. 2007;67:5141–7.PubMedCrossRef Cheng J, et al. Human macrophages promote the motility and invasiveness of Osteopontin-knockdown tumor cells. Cancer Res. 2007;67:5141–7.PubMedCrossRef
8.
Zurück zum Zitat Tuck AB, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 1998;79:502–8.PubMedCrossRef Tuck AB, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 1998;79:502–8.PubMedCrossRef
9.
Zurück zum Zitat Ue T, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998;79:127–32.PubMedCrossRef Ue T, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998;79:127–32.PubMedCrossRef
10.
Zurück zum Zitat Shijubo N, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med. 1999;160:1269–73.PubMed Shijubo N, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med. 1999;160:1269–73.PubMed
11.
12.
Zurück zum Zitat Thalmann GN, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res. 1999;5:2271–7.PubMed Thalmann GN, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res. 1999;5:2271–7.PubMed
13.
Zurück zum Zitat Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int. 2002;52:19–24.PubMedCrossRef Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int. 2002;52:19–24.PubMedCrossRef
14.
Zurück zum Zitat Pan HW, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003;98:119–27.PubMedCrossRef Pan HW, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003;98:119–27.PubMedCrossRef
15.
Zurück zum Zitat Ramankulov A, et al. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol. 2007;133:643–52.PubMedCrossRef Ramankulov A, et al. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol. 2007;133:643–52.PubMedCrossRef
16.
Zurück zum Zitat Matusan K, Dordevic G, Stipic D, Mozetic V, Lucin K. Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol. 2006;94:325–31.PubMedCrossRef Matusan K, Dordevic G, Stipic D, Mozetic V, Lucin K. Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol. 2006;94:325–31.PubMedCrossRef
17.
Zurück zum Zitat Wright SC, Zhong J, Larrick JW. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J. 1994;8:654–60.PubMed Wright SC, Zhong J, Larrick JW. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J. 1994;8:654–60.PubMed
18.
Zurück zum Zitat Yang J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997;275:1129–32.PubMedCrossRef Yang J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997;275:1129–32.PubMedCrossRef
19.
Zurück zum Zitat Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132–6.PubMedCrossRef Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132–6.PubMedCrossRef
20.
Zurück zum Zitat Reed JC. Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol. 1995;7:541–6.PubMedCrossRef Reed JC. Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol. 1995;7:541–6.PubMedCrossRef
21.
Zurück zum Zitat Rangaswami H, Kundu GC. Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncol Rep. 2007;18:909–15.PubMed Rangaswami H, Kundu GC. Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncol Rep. 2007;18:909–15.PubMed
22.
Zurück zum Zitat Mi Z, Guo H, Wai PY, Gao C, Kuo PC. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis. 2006;27:1134–45.PubMedCrossRef Mi Z, Guo H, Wai PY, Gao C, Kuo PC. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis. 2006;27:1134–45.PubMedCrossRef
23.
Zurück zum Zitat Samanna V, Wei H, Ego-Osuala D, Chellaiah MA. Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp Cell Res. 2006;312:2214–30.PubMedCrossRef Samanna V, Wei H, Ego-Osuala D, Chellaiah MA. Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp Cell Res. 2006;312:2214–30.PubMedCrossRef
24.
Zurück zum Zitat Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem. 2001;276:44926–35.PubMedCrossRef Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem. 2001;276:44926–35.PubMedCrossRef
Metadaten
Titel
Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells
verfasst von
Aimin Zhang
Yi Liu
Yizheng Shen
Youhe Xu
Xiangtie Li
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9356-z

Weitere Artikel der Ausgabe 4/2010

Medical Oncology 4/2010 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.